PAI
ABEO icon

Palo Alto Investors’s Abeona Therapeutics ABEO Stock Holding History

Palo Alto Investors’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$488K Hold
108,865
– – 0.07% 47
2025
Q4 		$574K Hold
108,865
– – 0.08% 46
2025
Q3 		$575K Hold
108,865
– – 0.11% 40
2025
Q2 		$618K Hold
108,865
– – 0.13% 41
2025
Q1 		$518K Hold
108,865
– – 0.1% 39
2024
Q4 		$606K Buy
108,865
+96,000
+746% +$591K 0.09% 38
2024
Q3 		$81.3K Buy
+12,865
New +$67.2K 0.01% 45

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Palo Alto Investors's ABEO Position: Q1 2026 in Review

Palo Alto Investors held its Abeona Therapeutics (ABEO) position steady in Q1 2026 at 108,865 shares worth $488K. The position accounts for 0.07% of the portfolio, ranked #47.

Palo Alto Investors first reported a position in ABEO in Q3 2024 and has held it in 7 quarters since. The position peaked at $618K in Q2 2025. 108 funds tracked by Wall St. Rank hold ABEO as of Q1 2026.

  • Palo Alto Investors held 108,865 shares of Abeona Therapeutics worth $488K as of Q1 2026.
  • Palo Alto Investors left its Abeona Therapeutics share count unchanged in Q1 2026.
  • Abeona Therapeutics made up 0.07% of Palo Alto Investors's portfolio in Q1 2026, its #47 holding.
  • Palo Alto Investors first reported a position in Abeona Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Palo Alto Investors's Abeona Therapeutics position peaked at $618K in Q2 2025.
  • 108 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2026.

Based on Palo Alto Investors's 13F filing for Q1 2026, filed 15 May 2026.